Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commercialization agreement for AVT10, Alvotech’s biosimilar candidate to Cimzia® (certolizumab pegol). “Our biosimilar candidate is the only one referencing Cimzia® that is under development globally and the reference product has carved out significant market share as treatment for chronic rheumatic diseases, especially for women of childbearing age. I’m very pleased to add it to our expanding commercial partnership with Advanz Pharma,” said Róbert Wessman, Chairman and CEO of Alvotech. “This agreement further strengthens our strategic partnership with Alvotech and supports our goal to expand access to high-quality biologics for patients in Europe. A proposed biosimilar to Cimzia® is a valuable addition to our sizable biosimilars pipeline,” said Steffen Wagner, CEO of Advanz Pharma. Certolizumab pegol is a TNF-alpha inhibitor indicated for a variety of inflammatory diseases. Worldwide sales of Cimzia® in 2024 were US$2.3 billion [1]. Alvotech and Advanz Pharma have previously entered into partnership agreements for biosimilar candidates to more than ten reference biologics. The companies expect to launch their first biosimilars in Europe in Q4 2025.